Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir Combined with Resveratrol or Thymosin for HBeAg Positive Chronic Hepatitis B
NCT03509688Completed
- Sponsor
- The First Hospital of Jilin University
- Start
- Nov 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of resveratrol in Chronic Hepatitis B (CHB) (3 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: HBeAg seroconversion rate at 48 weeks. Started Nov 2014; status: completed.
02
Drugs
resveratrol
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03509688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03509688.